Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 3, 2022.

The founder and chief medical officer of Omniscient Neurotechnology discussed how the use of machine learning and big data will be critical in revolutionizing our understanding of the brain and mental illnesses.

The founder and chief medical officer of Omniscient Neurotechnology commented on the areas of need with understanding the brain map and treating conditions with multiple pathway crossover. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is World MS Day.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 27, 2022.

David Evans, MBA, shared his experience from this year’s event and spoke about the progress that’s been made in advocating for patients in the last several years at the AAN's Neurology on the Hill conference.

Among participants with a high dementia polygenic risk score, the 12-year cumulative incidence of dementia was 4.3% for those with hypertension compared with 2.8% for those without.

The founder and chief medical officer of Omniscient Neurotechnology provided commentary on expanding the brain map, the use of advanced technology, and the need to familiarize clinicians with connectomics.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuropathic disorders.

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 20, 2022.

The founder and chief medical officer of Omniscient Neurotechnology discussed the idea behind connectomics and how AI revolutionizes large-scale brain data. [WATCH TIME: 4 minutes]

The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]

The blood test from Diadem SpA, which quantifies the AZ 284 peptide as readout of U-p53AZ, showed a significantly higher AUC in both time-independent and time-dependent prognostic analyses than gold standard testing.

The importance of addressing disorders of the brain cannot be overstated, and doing so will be essential to our generation and generations to come.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending May 14, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 13, 2022.

A Harris Poll conducted by Quest Diagnostics suggests that more than 65% of US physicians believe the Alzheimer disease field is on the cusp of a breakthrough, with more than 80% noting that earlier evaluation with blood testing may help improve therapeutic approaches.

The biologics license application includes data from the pivotal phase 2b proof-of-concept trial, its open-label extension, and the ongoing phase 3 Clarity AD study, which includes almost 1800 participants.

Baseline cognition and function were highly correlated in those with mixed Alzheimer and Lewy body dementia pathologies, but not in pure Alzheimer disease nor pure dementia with Lewy bodies.

Here's what is coming soon to NeurologyLive®.